PTGES3 Antibody

What is PTGES3 and why is it important in research?

PTGES3, also known as p23, is an enzyme encoded by the PTGES3 gene in humans. This protein functions as a chaperone required for proper functioning of glucocorticoid and other steroid receptors . The protein has dual functions:

• As an enzyme, it catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2)

• As a molecular chaperone, it supports various cellular processes including steroid receptor signaling

PTGES3 has gained significant research interest as a potential therapeutic target in various cancers, particularly breast and prostate cancer, where it plays roles in cell proliferation, migration, and androgen receptor function .

What are the standard applications for PTGES3 antibodies?

PTGES3 antibodies can be utilized in multiple experimental approaches:

How should researchers validate PTGES3 antibody specificity?

Proper validation is critical for reliable results. Recommended approaches include:

• Comparison with knockdown/knockout controls: This has been effectively demonstrated in breast cancer studies where siRNA knockdown of PTGES3 showed corresponding decreases in protein detection by antibodies

• Use of multiple antibodies targeting different epitopes of PTGES3

• Inclusion of positive controls (tissues/cells known to express PTGES3, such as breast cancer cell lines MDA-MB-231 and MCF-7)

• Inclusion of negative or low-expression controls (such as MCF-10A cells, which show lower PTGES3 expression compared to cancer lines)

What storage and handling considerations apply to PTGES3 antibodies?

For optimal stability and performance:

• Store at -20°C in buffer containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Avoid repeated freeze-thaw cycles by preparing working aliquots

• For antigen affinity-purified polyclonal antibodies, minimize exposure to light if fluorescently conjugated

• Follow manufacturer recommendations for reconstitution if lyophilized

How can PTGES3 antibodies be utilized in cancer research?

PTGES3 has emerged as a significant factor in cancer biology, particularly in breast and prostate cancers:

• Prognostic biomarker applications: PTGES3 was identified as part of a six-gene signature (including APOOL, BNIP3, F2RL2, HINT3, PTGES3, and RTN3) with prognostic value in breast cancer

• Therapeutic target assessment: Antibodies can monitor PTGES3 expression changes following treatment with potential inhibitors

• Mechanism investigation: Antibodies can detect PTGES3 in experiments assessing its role in cancer cell proliferation and migration

Case Study: In breast cancer research, PTGES3 antibodies helped establish that PTGES3 has the highest hazard ratio among a six-gene prognostic signature, correlating with poor survival outcomes. Immunochemical analysis with these antibodies confirmed increased PTGES3 protein levels in breast cancer samples compared to normal tissue .

What methodologies can assess PTGES3 inhibition in drug development research?

When investigating potential PTGES3 inhibitors for cancer therapy, researchers can employ several antibody-dependent approaches:

• Cell viability assessment: After treating cells with candidate PTGES3 inhibitors (such as gedunin, genistein, or diethylstilbestrol), antibodies can verify target engagement by measuring PTGES3 protein levels

• Expression correlation analysis: Western blots using PTGES3 antibodies can demonstrate reduced PTGES3 expression following drug treatment, as shown with genistein and diethylstilbestrol in breast cancer cells

• Functional screening: PTGES3 antibodies can be incorporated into assays that assess:

  • Cell proliferation inhibition

  • Migration suppression

  • Androgen receptor abundance reduction in prostate cancer models

Data from breast cancer studies showed that both genistein and diethylstilbestrol significantly reduced PTGES3 expression at both mRNA and protein levels while inhibiting cancer cell viability .

How can researchers investigate the dual functions of PTGES3 using antibodies?

PTGES3 performs both enzymatic and chaperone functions. Antibody-based approaches to dissect these activities include:

• Subcellular fractionation coupled with immunoblotting: This can detect PTGES3 distribution between nuclear and cytosolic compartments, relevant for its distinct functions

• Co-immunoprecipitation: Using PTGES3 antibodies to pull down protein complexes can reveal interactions with steroid receptors or HSP90 pathway components

• Chromatin immunoprecipitation (ChIP): Can detect PTGES3 association with androgen response elements, supporting its role in transcriptional regulation

What considerations apply when studying PTGES3 in different cancer types?

Different cancer contexts require tailored approaches:

When investigating PTGES3 in these contexts, antibody selection should consider:

• Reactivity across relevant species (human, mouse, rat) if using animal models

• Validation in the specific cancer cell lines of interest

• Ability to detect native protein in the particular subcellular compartment under study

What are the methodological approaches for testing potential PTGES3 inhibitors?

Researchers developing PTGES3 inhibitors can employ these antibody-dependent methods:

• Direct binding assessment:

  • Using antibodies to detect changes in PTGES3 levels after treatment

  • Comparing expression across treated and untreated samples

• Functional validation:

  • Cell viability assays (e.g., MTT assay) following inhibitor treatment, with antibody confirmation of PTGES3 reduction

  • Wound healing assays to assess migration inhibition, paired with PTGES3 expression analysis

• Mechanism investigation:

  • Detecting changes in PGE2 production (enzymatic function)

  • Assessing chaperone activity through steroid receptor function

Molecular docking studies have identified compounds like genistein (docking score -5.15 kcal/mol) and diethylstilbestrol (-3.28 kcal/mol) as potentially stronger PTGES3 binders than gedunin (-2.76 kcal/mol) . Antibody-based assays can validate these computational predictions.

What controls should be included when using PTGES3 antibodies?

Robust experimental design requires appropriate controls:

• Positive controls: Human cancer cell lines with known PTGES3 expression (MDA-MB-231, MCF-7)

• Comparative controls: Non-cancer cells (e.g., MCF-10A) that express lower levels of PTGES3

• Knockdown/silencing controls: Cells transfected with PTGES3 siRNA to demonstrate antibody specificity

• Loading controls: For Western blot normalization

• Isotype controls: For immunofluorescence or immunohistochemistry to control for non-specific binding

How can researchers address technical challenges with PTGES3 antibodies?

Common challenges and solutions include:

• Cross-reactivity concerns:

  • Use antibodies validated for specific reactivity (e.g., Human, Rat, Mouse)

  • Verify with knockdown experiments

  • Consider antibodies raised against specific protein regions if studying particular domains

• Detection of low expression:

  • Optimize antibody concentrations based on expression levels

  • Consider signal amplification methods for immunohistochemistry

  • Use more sensitive detection systems for Western blots

• Distinguishing subcellular localization:

  • Employ cellular fractionation followed by Western blotting

  • Use confocal microscopy with co-staining of subcellular markers

  • Optimize fixation methods to preserve both cytosolic and nuclear fractions

What specific protocols have been validated for PTGES3 antibody applications?

According to published research:

• Western blotting: Effective detection in mouse heart tissue at 1:200-1:1000 dilution

• Immunofluorescence: Validated in HeLa cells at 1:10-1:100 dilution

• siRNA validation: Transient transfection of PTGES3 siRNA in breast cancer cell lines has been used to confirm antibody specificity

• Drug response assessment: Protocols for measuring PTGES3 expression changes following treatment with genistein and diethylstilbestrol have been established

How might PTGES3 antibodies contribute to emerging cancer therapies?

PTGES3 antibodies will likely play crucial roles in:

• Validating computational drug screening approaches that identify novel PTGES3 inhibitors

• Developing companion diagnostics to identify patients who might benefit from PTGES3-targeted therapies

• Monitoring treatment response and resistance mechanisms

• Understanding the relationship between PTGES3 expression and immune infiltration in tumors

What new methodologies might enhance PTGES3 antibody applications?

Emerging technologies that could advance PTGES3 research include:

• Multiplexed immunofluorescence to simultaneously detect PTGES3 and interacting partners

• Mass spectrometry-based immunoprecipitation to identify novel PTGES3 protein interactions

• Single-cell analysis to understand heterogeneity of PTGES3 expression in tumor microenvironments

• Development of antibodies specific to post-translationally modified forms of PTGES3